Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection a human challenge study
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms CHIMP
- 08 Jun 2024 Status changed from recruiting to completed.
- 08 Nov 2021 New trial record